QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mangold, J. B. Articles by Rordorf, C. Search for Related Content PubMed PubMed Citation Articles by Mangold, J. B. Articles by Rordorf, C.

PHARMACOKINETICS AND METABOLISM OF LUMIRACOXIB IN HEALTHY MALE SUBJECTS

Preclinical Safety–ADME, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (J.B.M., H.G., L.C.R.); Clinical Pharmacology, Novartis Pharmaceuticals Research Centre, Horsham, United Kingdom (J.B.); Inveresk Research, Tranent,Scotland (J.D.); and Novartis Pharma AG, Basel, Switzerland (C.R.)

Lumiracoxib (Prexige; 2-[(2-fluoro-6-chlorophenyl)amino]-5-methyl-benzeneacetic acid) is a novel, chemically distinct cyclooxygenase-2 selective inhibitor, which has been developed for the treatment of osteoarthritis, rheumatoid arthritis, and acute pain. The absorption, metabolism, disposition, and mass balance of [¹⁴C]lumiracoxib were investigated in four healthy male subjects after a single 400-mg oral dose. Serial blood and complete urine and feces were collected for 168 h postdose. Lumiracoxib was rapidly absorbed, achieving mean plasma concentrations >1 µg/ml within 1 h of dosing. Unchanged drug in plasma accounted for 81 to 91% of radioactivity up to 2.5 h postdose, suggesting a modest first-pass effect; unchanged drug was the major circulating component in plasma, accounting for 43% of the AUC_{0 to 24h}. The terminal half-life of lumiracoxib in plasma was 6.5 h. Major plasma metabolites were the 5-carboxy, 4'-hydroxy, and 4'-hydroxy-5-carboxy derivatives. Excretion involved both renal (54.1%) and fecal (42.7%) routes, and dose recovery was almost complete (96.8%). Lumiracoxib was extensively metabolized before excretion, with little unchanged drug in urine (3.3% of dose) or feces (2.0% of dose). The major metabolic pathways of lumiracoxib were oxidation of the 5-methyl group and hydroxylation of the dihaloaromatic ring. Glucuronic acid conjugates of lumiracoxib metabolites (and to a minor extent lumiracoxib itself) were identified, although there was no evidence of cysteine, mercapturic acid, or glutathione conjugates. In summary, orally administered lumiracoxib is rapidly absorbed and undergoes extensive metabolism before excretion via urine and feces, with no evidence of formation of potentially reactive metabolites.

This article has been cited by other articles:

				Y. Li, J. G. Slatter, Z. Zhang, Y. Li, G. A. Doss, M. P. Braun, R. A. Stearns, D. C. Dean, T. A. Baillie, and W. Tang In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations Drug Metab. Dispos., February 1, 2008; 36(2): 469 - 473. [Abstract] [Full Text] [PDF]

				K. Brune and D. E. Furst Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology, June 1, 2007; 46(6): 911 - 919. [Abstract] [Full Text] [PDF]

				A. D. Rodrigues IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME? Drug Metab. Dispos., November 1, 2005; 33(11): 1567 - 1575. [Abstract] [Full Text] [PDF]

				J. Jermany, J. Branson, R. Schmouder, M. Guillaume, and C. Rordorf Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects J. Clin. Pharmacol., October 1, 2005; 45(10): 1172 - 1178. [Abstract] [Full Text] [PDF]

				A. S. C. Fabricio, F. H. Veiga, R. Cristofoletti, P. Navarra, and G. E. P. Souza The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2005; 288(3): R671 - R677. [Abstract] [Full Text] [PDF]

				H Tannenbaum, F Berenbaum, J-Y Reginster, J Zacher, J Robinson, G Poor, H Bliddal, D Uebelhart, S Adami, F Navarro, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib Ann Rheum Dis, November 1, 2004; 63(11): 1419 - 1426. [Abstract] [Full Text] [PDF]